FTC Allows Genzyme/Novazyme Merger, Finds No Product Development Delay
Executive Summary
The merger of Genzyme and Novazyme does not merit antitrust activity because it does not result in the delay of Pompe therapy development, the Federal Trade Commission said Jan. 13